BACKGROUND: The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. METHODS: In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment withchemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients tochemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation. RESULTS: The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8 percent among patients who did not receive chemotherapy (P=0.009). The benefit of chemotherapy persisted after adjustment for major prognostic factors. CONCLUSIONS:Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival. Copyright 2004 Massachusetts Medical Society
RCT Entities:
BACKGROUND: The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. METHODS: In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation. RESULTS: The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8 percent among patients who did not receive chemotherapy (P=0.009). The benefit of chemotherapy persisted after adjustment for major prognostic factors. CONCLUSIONS: Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival. Copyright 2004 Massachusetts Medical Society
Authors: Skye C Mayo; Hari Nathan; John L Cameron; Kelly Olino; Barish H Edil; Joseph M Herman; Kenzo Hirose; Richard D Schulick; Michael A Choti; Christopher L Wolfgang; Timothy M Pawlik Journal: Cancer Date: 2011-09-20 Impact factor: 6.860
Authors: Christoph M Burdelski; Matthias Reeh; Dean Bogoevski; Florian Gebauer; Michael Tachezy; Yogesh K Vashist; Guellue Cataldegirmen; Emre Yekebas; Jakob R Izbicki; Maximilian Bockhorn Journal: World J Surg Date: 2011-12 Impact factor: 3.352
Authors: Ross A Abrams; Kathryn A Winter; William F Regine; Howard Safran; John P Hoffman; Robert Lustig; Andre A Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-01 Impact factor: 7.038
Authors: Zijian Yang; Michael J LaRiviere; Jina Ko; Jacob E Till; Theresa Christensen; Stephanie S Yee; Taylor A Black; Kyle Tien; Andrew Lin; Hanfei Shen; Neha Bhagwat; Daniel Herman; Andrew Adallah; Mark H O'Hara; Charles M Vollmer; Bryson W Katona; Ben Z Stanger; David Issadore; Erica L Carpenter Journal: Clin Cancer Res Date: 2020-04-16 Impact factor: 12.531
Authors: Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss Journal: Ann Surg Oncol Date: 2014-04-26 Impact factor: 5.344
Authors: Steve Walston; Joseph Salloum; Carmine Grieco; Evan Wuthrick; Dayssy A Diaz; Christian Barney; Andrei Manilchuk; Carl Schmidt; Mary Dillhoff; Timothy M Pawlik; Terence M Williams Journal: Am J Clin Oncol Date: 2018-12 Impact factor: 2.339